Amylin Pharmaceuticals

Contact
amylin.com
+1858552-2200

Amylin Pharmaceuticals, Inc.

9360 Towne Centre Drive
92121 San Diego
USA
+1858552-2200
amylin.com
Contact
Profile Products News
Contact

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California.

Read more about Amylin Pharmaceuticals
Facts about Amylin Pharmaceuticals
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Amylin Pharmaceuticals

Product portfolio

Show all

News about Amylin Pharmaceuticals

Amylin Pharmaceuticals

08-Aug-2011 | research and development

Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity

Collaboration Will Explore Potential of Other Assets to Address Obesity Epidemic

Read news
Amylin Pharmaceuticals

21-Oct-2010 | research and development

Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a complete ...

Read news
Amylin Pharmaceuticals

03-Jun-2010 | people

Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development

Orville Kolterman, MD Named Senior Vice President, Chief Medical Officer

Read news
Amylin Pharmaceuticals

03-Nov-2009 | research and development

BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ...

Read news
Amylin Pharmaceuticals

02-Nov-2009 | business & finance

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that they have entered into a worldwide exclusive license, development and ...

Read news
Amylin Pharmaceuticals

14-Sep-2009 | business & finance

Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for Peptide Hybrid

Program will Focus on the Potential Treatment of Diabetes

Read news
Amylin Pharmaceuticals

25-Aug-2009 | people

Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board

Amylin Pharmaceuticals, Inc. announced that its Board of Directors has elected Paulo F. Costa as Chairman of the Board, effective immediately. Mr. Costa ...

Read news
Amylin Pharmaceuticals

13-Jul-2009 | research and development

Amylin Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

Amylin Pharmaceuticals, Inc. announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising ...

Read news
Show more news about Amylin Pharmaceuticals

Here you will find Amylin Pharmaceuticals, Inc.